Research-use-only guide. It covers what ipamorelin is and how to judge supplier paperwork. It gives no dosing, cycling or health advice. Supplier links are affiliate links; see below.
Five residues, three of them unusual
Ipamorelin looks tiny next to most compounds in this directory. It is a pentapeptide, five residues long, with a mass of about 712 daltons. But a quick glance at the sequence shows why it is not a simple molecule. Written out, it reads Aib-His-D-2Nal-D-Phe-Lys-NH2, and only two of those pieces, histidine and lysine, are ordinary amino acids of the kind found in natural proteins. The others are laboratory inventions: aminoisobutyric acid at the front, the mirror-image form of a bulky naphthylalanine, the mirror-image form of phenylalanine, and an amide cap at the end instead of the usual carboxylic acid.
Those substitutions are not decoration. They came out of a medicinal chemistry program at the Danish company Novo Nordisk in the 1990s, where researchers were hunting for small molecules that could trigger the body's growth-hormone release machinery. Natural amino acids are broken down quickly by enzymes, and swapping in mirror-image or oddly shaped residues makes a peptide far more durable. It also makes it harder to manufacture, since each non-natural building block must be bought, coupled efficiently, and verified.
What it targets, in plain terms
Growth hormone release from the pituitary gland is governed by several signals. One is GHRH, the hormone that tesamorelin imitates; see our tesamorelin guide. Another is ghrelin, a peptide made mainly in the stomach. Ghrelin acts on a receptor called GHS-R1a, and ipamorelin belongs to a family of compounds called growth hormone secretagogues, which stimulate that receptor. In early pharmacology papers, it was described as unusually selective: in animal experiments it raised growth hormone with little effect on other pituitary hormones such as ACTH or cortisol, in contrast to some earlier compounds in the family.
That selectivity claim is repeated so often online that it is worth being careful about its status. It comes from preclinical work and a limited number of early human studies, not from large modern trials. Ipamorelin was developed through mid-stage clinical testing for a hospital-related bowel problem, but the program did not result in an approved medicine. It has no marketing authorisation in any major jurisdiction, and it is on the World Anti-Doping Agency's prohibited list. This site discusses it as a research material only.
Why the mirror-image residues matter on a COA
Amino acids come in two mirror-image forms, designated L and D, like left and right hands. Natural proteins use L almost exclusively. Ipamorelin deliberately includes D forms, and that creates a quality-control problem that does not exist for ordinary peptides: a mistake in the chirality of one residue produces a molecule with exactly the same mass as the correct one. Mass spectrometry cannot tell them apart. The only way to catch such an error is chromatography, since the diastereomer will usually elute at a slightly different time, or specialised chiral analysis.
This has two consequences for buyers. First, a mass spectrum alone is weaker evidence of identity here than it would be for BPC-157. Second, the HPLC trace deserves a closer look than usual. A small peak sitting immediately before or after the main one could be an epimer. Good suppliers show the entire trace, state the method, and explain what the minor peaks are. Poor ones show only a clean-looking percentage.
A development program that went quiet
It helps to remember how ipamorelin ended up in the research-chemical market at all. Novo Nordisk characterised it, patented it and tested it, and then licensed the compound onward; a later sponsor ran a mid-stage trial in people recovering from abdominal surgery, aiming at a gut-motility problem rather than anything related to growth. That study did not lead to an approved product, and development stopped. What remained was a well-characterised molecule with a published structure and a straightforward synthetic route, which is exactly the profile that attracts research suppliers. I have not verified the current patent position, and nothing here should be read as a statement about it. The point is simply that a short, fully published structure is easy for any laboratory to reproduce, for better and for worse. There is therefore no pharmaceutical reference lot to compare against, no pharmacopoeial monograph, and no regulator checking what is sold. That is no reason for alarm in itself, but it explains why the supplier's own documentation has to carry so much weight, and why we put so much emphasis on it when we review the companies behind these listings.
Reading the paperwork
| Expected mass | About 712 Da (monoisotopic around 711.4). A mass in this region confirms the composition but not the chirality. |
|---|---|
| HPLC trace | The whole chart. Look for small flanking peaks, which may be stereoisomers or deletion products. |
| Terminal amide | The product carries an amide on the C-terminus. A free-acid version would weigh about 1 Da more; a careful lab notes this. |
| Counter-ion and content | Acetate or TFA salt. Net peptide content can be well below the label weight for a small, polar peptide like this. |
| Batch details | Lot, date and laboratory matching the vial. |
Blends and look-alike names
Ipamorelin is frequently sold pre-mixed with CJC-1295, and the combined products carry compact names that obscure what is inside. A mixed vial needs a COA that identifies both components and states how much of each was added. Without this, the label is a claim, not a measurement. Some listings name the CJC component ambiguously, and as our CJC-1295 guide explains, there are two chemically different molecules sold under that label. Vortex, for instance, lists ipamorelin as a standalone vial and also in a blend with CJC-1295 without DAC. Check the product title carefully before comparing prices.
Another source of confusion is the family of related secretagogues, including GHRP-2, GHRP-6 and hexarelin, which are sometimes lumped together. They are different molecules with different properties and different sequences. A listing for "GHRP" without a specific compound name should be treated as incomplete.
Where to find it
Three suppliers in our directory list ipamorelin. I have not purchased from them for this page; the notes reflect public listings. Please check each batch's paperwork before you rely on any of them.
Iron Peptides lists a 5 mg ipamorelin vial. Code IRONMAN gives 10% off. See our Iron Peptides review; the company is a sponsored listing on this site.
Next Gen Peps lists ipamorelin in its catalog. See our Next Gen Peps review.
Vortex Research lists ipamorelin under the short name "Ipamorelin" and sells it alongside blends. Its PEPPERS code is advertised at 30% off. It has not been reviewed here yet.
All three are affiliate links. PeptideSuppliers.org may earn a commission if you buy, at no cost to you. This does not change our ratings, and the suppliers appear in alphabetical order. The disclosure page has the details.
Questions that come up
Is ipamorelin a hormone?
No. It is a synthetic peptide that mimics one aspect of a natural signal. It was designed in a lab and has no natural counterpart with its sequence.
Why do prices vary so widely for such a short peptide?
Non-natural building blocks cost more than standard ones, and quality varies in whether those blocks were controlled for chirality. A low price with a thin COA is not necessarily a bargain.
Does a clean mass spectrum prove the right molecule?
It proves the composition, not the three-dimensional arrangement. For a peptide with D-amino acids, chromatography is the stronger check on chirality.
For the full list of suppliers, see the supplier database.
For laboratory research use only. Not medical advice; no claims about safety, legality or fitness for any use. See the medical disclaimer.